LivaNova plc — Q1 2022 Form 10-Q Summary
Business Context and Reporting Period
LivaNova is a global medical device company operating through Cardiopulmonary, Neuromodulation and Advanced Circulatory Support segments. This unaudited Form 10-Q covers the three months ended March 31, 2022, with comparisons to the revised three-month period ended March 31, 2021. Financial statements are presented in U.S. dollars under U.S. GAAP.
Financial Performance and Key Metrics
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Net sales | $240.2 million | $247.6 million | (3.0%) |
| Gross profit | $168.4 million | $163.4 million | 3.1% |
| Gross margin | 70.1% | 66.0% | +4.1 percentage points |
| Operating income (loss) | $9.5 million | $(5.7) million | Improved |
| Operating margin | 4.0% | (2.3%) | +6.3 percentage points |
| Net income (loss) | $3.0 million | $(30.8) million | Improved |
| Diluted income (loss) per share | $0.06 | $(0.63) | Improved |
| Cash flow from operations | $25.8 million | $19.5 million | +$6.3 million |
- Cardiopulmonary sales increased 7.7% to $117.1 million, supported by higher cardiac procedure volumes and heart-lung machine sales, partly offset by approximately $5 million of unfavorable foreign exchange effects.
- Neuromodulation sales increased 6.3% to $110.2 million, driven primarily by replacement implants and growth across all regions.
- Advanced Circulatory Support sales decreased 10.1% to $11.7 million, primarily due to fewer ECMO patients, hospital staffing shortages and less severe COVID-19 cases.
- Gross margin improved primarily from favorable product mix, the prior-year comparison effect from the Heart Valve divestiture and contingent consideration fair-value effects.
- SG&A increased to $118.5 million, or 49.3% of sales, partly due to ALung-related business development costs and higher 3T legal costs. R&D declined to $40.9 million, or 17.0% of sales.
- Interest expense declined to $7.8 million from $15.9 million, primarily following repayment of the prior senior secured term loan in 2021.
- Foreign exchange and other gains were $3.9 million versus a $6.4 million loss in the prior-year period. The 2022 amount included an $11.0 million gain on the exchangeable notes fair-value adjustment and a $9.9 million loss on capped call derivatives.
- The effective tax rate was 45.6%, compared with negative 9.4% in Q1 2021, reflecting changes in valuation allowances and the geographic mix of pretax income.
Liquidity, Debt and Cash Flow
- Cash and cash equivalents were $128.7 million at March 31, 2022, compared with $208.0 million at December 31, 2021. Restricted cash was $313.6 million, resulting in total cash, cash equivalents and restricted cash of $442.4 million.
- Operating activities provided $25.8 million; investing activities used $5.5 million, including $5.2 million for property, plant and equipment; and financing activities provided $214.9 million.
- Total debt obligations were approximately $460.6 million, including $455.8 million of long-term debt and $4.8 million of current debt. The balance included $220.0 million drawn under a new Bridge Loan Facility and $228.5 million of cash exchangeable senior notes.
- The Bridge Loan Facility matures June 16, 2023, carries an effective interest rate of 11.04% at March 31, 2022, and has a maximum margin of 5.25% over adjusted SOFR. It is subject to mandatory prepayment under specified circumstances and is expected to become a current liability at the end of Q2 2022.
- The company had $125.0 million available under its revolving credit facility and no outstanding borrowings under that facility at March 31, 2022.
- Management stated that available liquidity, operating cash flow and borrowing capacity are expected to fund operating, capital, research and development, acquisition and debt-service needs for at least the next twelve months. Management also expects to seek refinancing or replacement financing for the Bridge Loan Facility, but provided no assurance that financing will be available on acceptable terms or on a timely basis.
Material Changes Versus the Prior Comparable Period
- Revenue declined 3.0% overall because growth in Cardiopulmonary and Neuromodulation was more than offset by the absence of Heart Valve business revenue following its June 2021 divestiture and weaker Advanced Circulatory Support revenue.
- Profitability improved substantially: the company moved from an operating loss and net loss to operating income and net income. Lower restructuring and litigation-related expenses, better gross margin, lower interest expense and favorable derivative fair-value movements were significant contributors.
- Reportable segment income increased 105.3% to $15.9 million. Cardiopulmonary segment income rose to $6.9 million, Neuromodulation segment income rose to $37.5 million, while Advanced Circulatory Support moved to a $5.4 million loss.
- The company posted a total comprehensive loss of $6.0 million, primarily due to an $8.3 million unfavorable foreign currency translation adjustment and a $0.7 million derivative loss.
- Prior-period financial statements were revised for a foreign-currency error affecting inventory and cost of sales. The revised Q1 2021 net loss was $30.8 million, versus $29.7 million previously reported.
Guidance, Outlook, Commentary and Risks
- No specific quantitative full-year revenue, earnings or margin guidance is provided in the filing. Management cautions that quarterly results are not necessarily indicative of full-year performance.
- COVID-19 continues to create unpredictable demand, procedure delays, staffing shortages, supply-chain disruption, inflation and higher freight and labor costs. Cardiopulmonary procedure volumes were recovering, while Neuromodulation and Advanced Circulatory Support continued to experience COVID-related headwinds.
- The Russia-Ukraine conflict, sanctions, potential raw-material impacts and broader economic uncertainty could materially affect operations. Russia and Ukraine represented approximately 1% of 2021 total net sales.
- The Italian SNIA environmental litigation remains a major contingency. The Court of Appeal ordered approximately €453.6 million of damages, while LivaNova appealed to the Italian Supreme Court. Payment was suspended pending appeal after the company posted a €270.0 million bank guarantee backed by $313.6 million of restricted cash.
- The company had a $36.2 million provision for 3T Heater-Cooler product-liability matters and approximately $38.3 million accrued for Saluggia hazardous-substance obligations. It was aware of approximately 90 filed and unfiled 3T-related claims worldwide as of May 4, 2022.
- An FDA close-out inspection of the Munich facility on April 28, 2022 resulted in three Form 483 observations involving design validation, process validation and complaint investigations. The outcome and acceptance of corrective actions remain uncertain.
- On May 2, 2022, after quarter-end, LivaNova acquired the remaining 97% of ALung Technologies for $10.0 million at closing, with potential contingent consideration of up to $100.0 million based on sales milestones through 2027.
- Other significant risks include medical-device regulation and reimbursement, product liability, clinical-trial execution, intellectual-property protection, foreign exchange, interest rates, cybersecurity, labor shortages, supplier concentration and the ability to refinance the Bridge Loan Facility.
Most Important Facts for Investors to Verify
- Whether the Italian Supreme Court ultimately upholds, reduces or overturns the SNIA liability and the timing and availability of the related restricted cash.
- Whether LivaNova can refinance or repay the Bridge Loan Facility before maturity and manage the expected current-liability classification after Q2 2022.
- Progress toward resolution of the FDA Form 483 observations and closure of the 2015 Warning Letter.
- The scale and financial impact of remaining 3T product-liability claims and other legal proceedings.
- Whether Cardiopulmonary and Neuromodulation growth can offset ongoing weakness in Advanced Circulatory Support and the loss of Heart Valve revenue from the prior-year comparison.
- The financial contribution, contingent consideration exposure and integration risks associated with the post-quarter-end ALung acquisition.
- Actual effects of COVID-19, supply-chain constraints, inflation, labor shortages and the Russia-Ukraine conflict on demand, costs and production.